SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. _____)*

  

 

RAPT Therapeutics, Inc.

(Name of Issuer)

 

 

Common Stock

(Title of Class of Securities)

 

 

75382E109

(CUSIP Number)

 

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

x Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)

 

 

 

Page 1 of 9

Exhibit Index on Page 8

 

 

 

CUSIP #75382E109 Page 2 of 9

  

1 NAME OF REPORTING PERSONS                      Kleiner Perkins Caufield & Byers XV, LLC (“KPCB XV”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)       ¨        (b)       x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
3,444,199 shares, except that KPCB XV Associates, LLC (“Associates”), the managing member of KPCB XV, may be deemed to have sole power to vote these shares.
  6 SHARED VOTING POWER
See response to row 5.
  7 SOLE DISPOSITIVE POWER
3,444,199 shares, except that Associates, the managing member of KPCB XV, may be deemed to have sole power to dispose of these shares.
  8 SHARED DISPOSITIVE POWER
See response to row 7.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,444,199
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 15.8%
12 TYPE OF REPORTING PERSON OO

 

 

  

CUSIP #75382E109 Page 3 of 9

  

1 NAME OF REPORTING PERSONS                     KPCB XV Founders Fund, LLC (“KPCB XV Founders”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)     ¨     (b)   x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
102,864 shares, except that Associates, the managing member of KPCB XV Founders, may be deemed to have sole power to vote these shares.
  6 SHARED VOTING POWER
See response to row 5.
  7 SOLE DISPOSITIVE POWER
102,864 shares, except that Associates, the managing member of KPCB XV Founders, may be deemed to have sole power to dispose of these shares.
  8 SHARED DISPOSITIVE POWER
See response to row 7.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
102,864
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.5%
12 TYPE OF REPORTING PERSON OO

  

 

 

CUSIP #75382E109 Page 4 of 9

 

1 NAME OF REPORTING PERSONS                    KPCB XV Associates, LLC
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)       ¨        (b)      x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
5 SOLE VOTING POWER
3,547,063 shares, of which 3,444,199 are directly owned by KPCB XV and 102,864 are directly owned by KPCB XV Founders.  Associates, the managing member of KPCB XV and KPCB XV Founders, may be deemed to have sole power to vote these shares.
  6 SHARED VOTING POWER
See response to row 5.
  7 SOLE DISPOSITIVE POWER
3,547,063 shares, of which 3,444,199 are directly owned by KPCB XV and 102,864 are directly owned by KPCB XV Founders.  Associates, the managing member of KPCB XV and KPCB XV Founders, may be deemed to have sole power to dispose of these shares.
  8 SHARED DISPOSITIVE POWER
See response to row 7.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,547,063
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 16.3%
12 TYPE OF REPORTING PERSON OO

 

 

 

CUSIP #75382E109 Page 5 of 9

 

ITEM 1(A). NAME OF ISSUER
   
  RAPT Therapeutics, Inc. (the “Issuer”)

 

ITEM 1(B). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

 
  561 Eccles Avenue
  South San Francisco, CA 94080

 

ITEM 2(A). NAME OF PERSONS FILING
   
  This Schedule is filed by Kleiner Perkins Caufield & Byers XV, LLC, a Delaware limited liability company, KPCB XV Founders Fund, LLC, a Delaware limited liability company, and KPCB XV Associates, LLC, a Delaware limited liability company. The foregoing entities are collectively referred to as the “Reporting Persons.”

 

ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE

 

The address for each of the Reporting Persons is:

 

c/o Kleiner Perkins Caufield & Byers
2750 Sand Hill Road
Menlo Park, California 94025

 

ITEM 2(C). CITIZENSHIP

 
  See Row 4 of cover page for each Reporting Person.

 

ITEM 2(D). TITLE OF CLASS OF SECURITIES

Common Stock, $.0001 par value

 

ITEM 2(E).

CUSIP NUMBER

 

75382E109

 

ITEM 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

 

 

CUSIP #75382E109 Page 6 of 9

 

ITEM 4. OWNERSHIP

 

The following information with respect to the ownership of the ordinary shares of the Issuer by the persons filing this Statement is provided as of December 31, 2019:

 

(a) Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

 

(b) Percent of Class:

See Row 11 of cover page for each Reporting Person.

 

(c) Number of shares as to which such person has:

 

(i) Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

 

(ii) Shared power to vote or to direct the vote:

 

See Row 6 of cover page for each Reporting Person.

 

(iii) Sole power to dispose or to direct the disposition of:

 

See Row 7 of cover page for each Reporting Person.

 

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

 

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

 

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Under certain circumstances set forth in the limited liability company agreements of the Reporting Persons, the members of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a member.

 

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable.

 

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable.

 

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not applicable.

 

ITEM 10. CERTIFICATION.

Not applicable.

 

 

 

CUSIP #75382E109 Page 7 of 9

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 12, 2020
   
  KLEINER PERKINS CAUFIELD & BYERS XV, LLC, a
Delaware limited liability company
   
  By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer
   
   
  KPCB XV FOUNDERS FUND, LLC, a Delaware limited
liability company
   
  By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer
   
   
  KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer

 

 

 

CUSIP #75382E109 Page 8 of 9

 

EXHIBIT INDEX 

 

  Found on
Sequentially
Exhibit Numbered Page
Exhibit A:  Agreement of Joint Filing 9

 

 

 

CUSIP #75382E109 Page 9 of 9

 

exhibit A

 

Agreement of Joint Filing

 

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

 

   
Date: February 12, 2020  
   
  KLEINER PERKINS CAUFIELD & BYERS XV, LLC, a
Delaware limited liability company
   
  By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer
   
   
  KPCB XV FOUNDERS FUND, LLC, a Delaware limited
liability company
   
  By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer
   
   
  KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company
   
  By: /s/ Susan Biglieri
    Susan Biglieri
    Chief Financial Officer

 

 

  

 

RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more RAPT Therapeutics Charts.
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more RAPT Therapeutics Charts.